Lomass Soliman | Young Researcher Award | Pharmaceutical Sciences

Young Researcher Award

 Lomass Soliman
Affiliation Institute of Pharmaceutical Technology and Regulatory Affairs
Country Hungary
Scoholar ID 6osAAAAJ
Documents 5
Citations 23
h-index 3
Subject Area Pharmaceutical Sciences
Event International Research Awards on Network Science & Graph Analytics

Lomass Soliman
Institute of Pharmaceutical technology and regulatory affairs

 Lomass Soliman The recognition is associated with the International Research Awards on Network Science & Graph Analytics and is intended to highlight emerging researchers whose scholarly activities demonstrate developing expertise, research engagement, and potential for continued contribution to their discipline.

Abstract

This academic recognition profile presents Lomass Soliman in the context of the Young Researcher Award. Soliman is affiliated with the Institute of Pharmaceutical Technology and Regulatory Affairs at the University of Szeged in Hungary and works within the broad field of pharmaceutical sciences. The supplied scholarly indicators record five documents, 23 citations, and an h-index of 3. These metrics describe an emerging publication and citation record and may be considered alongside the quality, originality, relevance, and documented contribution of individual research outputs. Bibliometric indicators are generally most informative when interpreted together with qualitative evidence of scholarly contribution rather than as standalone measures of research quality. [2]

Keywords

  • Lomass Soliman
  • Young Researcher Award
  • Pharmaceutical Sciences
  • Pharmaceutical Technology
  • Regulatory Affairs
  • University of Szeged
  • Research Recognition
  • Bibliometric Indicators

Introduction

Young researcher recognition generally emphasizes the development of an independent scholarly profile, research productivity, methodological competence, and potential for sustained contribution. Within pharmaceutical sciences, research may encompass drug development, pharmaceutical formulation, delivery systems, analytical methods, manufacturing technologies, quality considerations, and regulatory frameworks. The Institute of Pharmaceutical Technology and Regulatory Affairs at the University of Szeged provides an academic setting relevant to these interdisciplinary areas.

Evaluation of early-career researchers benefits from combining quantitative measures with qualitative assessment. Publication counts and citation indicators can provide useful evidence of scholarly visibility, while peer-reviewed research, methodological rigor, originality, reproducibility, and relevance offer additional dimensions for evaluation. [1]

Research Profile

Lomass Soliman’s supplied academic information places the researcher within Pharmaceutical Sciences, with an institutional affiliation in pharmaceutical technology and regulatory affairs. The available Google Scholar identifier is BPP-6osAAAAJ, while the supplied bibliometric record reports five documents, 23 citations, and an h-index of 3. [3]

The combination of pharmaceutical technology and regulatory affairs represents an interdisciplinary research environment in which scientific development can intersect with formulation, product quality, evaluation, and regulatory considerations. Further assessment of the research profile would appropriately consider the specific topics, study designs, venues, and contribution statements associated with the documented publications.

Research Contributions

Based on the supplied information, Soliman’s research profile is situated within pharmaceutical sciences and the institutional domain of pharmaceutical technology and regulatory affairs. The available record supports recognition of an emerging scholarly trajectory rather than a definitive assessment of a specific research breakthrough. Detailed contribution analysis should examine the originality, scientific methodology, reproducibility, and practical or regulatory relevance of individual publications.

  • Development of scholarly activity within pharmaceutical sciences.
  • Engagement with research at the intersection of pharmaceutical technology and regulatory affairs.
  • Establishment of an emerging citation and publication record.
  • Potential for continued interdisciplinary research and professional development.

Publications

The supplied profile reports five scholarly documents associated with the researcher. Individual publication titles, journals, publication years, authorship positions, and DOI identifiers were not provided in the source information supplied for this page. Consequently, specific publications and DOI records should be verified against authoritative bibliographic databases before being added to a formal publication list. This approach avoids attributing publications or identifiers without adequate source verification.

Research Impact

The supplied metrics indicate 23 citations across five documents and an h-index of 3. Citation counts can provide an indication of scholarly uptake, but their interpretation depends on field, publication age, document type, collaboration patterns, and database coverage. [2] For a young researcher, these indicators may be considered as part of a broader assessment that includes research quality, contribution to collaborative projects, methodological development, and prospects for future work.

Award Suitability

Lomass Soliman’s supplied academic profile is consistent with the general concept of a Young Researcher Award because it documents active scholarly work in Pharmaceutical Sciences and an identifiable record of publications and citations. The affiliation with the University of Szeged further establishes an academic research context. Final award eligibility and selection, however, should be determined according to the official criteria of the International Research Awards on Network Science & Graph Analytics and through the event’s formal review process.

Relevant evaluation may include the quality and originality of publications, demonstrated research contribution, academic progression, scholarly visibility, and the potential for continued impact. The current bibliometric indicators can serve as supporting evidence but should not substitute for peer or committee assessment.

Conclusion

Lomass Soliman represents an emerging researcher in Pharmaceutical Sciences affiliated with the University of Szeged in Hungary. The supplied record of five documents, 23 citations, and an h-index of 3 provides a measurable foundation for evaluating early scholarly development.

Within the Young Researcher Award context, the profile may be considered alongside publication quality, research originality, contribution, and future potential. Further bibliographic verification and review of individual research outputs would strengthen a comprehensive assessment.

References

  1. International Committee of Medical Journal Editors. (n.d.). Recommendations for the conduct, reporting, editing, and publication of scholarly work in medical journals.https://www.icmje.org/recommendations/
  2. Hirsch, J. E. (2005). An index to quantify an individual’s scientific research output. Proceedings of the National Academy of Sciences, 102(46), 16569–16572.https://doi.org/10.1073/pnas.0507655102
  3. Google Scholar. (n.d.). Google Scholar profile: Lomass Soliman, profile ID BPP-6osAAAAJ.https://scholar.google.com/citations?hl=en&user=BPP-6osAAAAJ
  4. University of Szeged. (n.d.). Institute of Pharmaceutical Technology and Regulatory Affairs.https://www.u-szeged.hu/

Essa M. Saied | Pharmaceutical Sciences | Research Excellence Award

Dr. Essa M. Saied | Pharmaceutical Sciences | Research Excellence Award

Humboldt University of Berlin | Germany

Dr. Essa M. Saied is a distinguished Senior Researcher in the Bioorganic Chemistry Department at Humboldt University of Berlin, Germany, and an Associate Professor of Biochemistry in the Chemistry Department at Suez Canal University, Egypt. His research spans the fields of bioorganic and biochemistry with strong expertise in synthetic medicinal chemistry, heterocyclic chemistry, small-molecule drug discovery, high-throughput screening, molecular modelling, virtual screening, enzymatic assays, anticancer research, and lipid chemistry in human diseases. He earned his Ph.D. in Organic and Bioorganic Chemistry from Humboldt-Universität zu Berlin in 2017 with a thesis on “Synthesis and Characterization of Inhibitors of Sphingolipid Metabolism,” following a Master of Science in Organic Chemistry from Suez Canal University with an excellent grade and earlier pre-master coursework in Organic, Physical, and Inorganic Chemistry. Dr. Saied has secured several competitive grants and fellowships, including the Yousef Jameel Ph.D. Fellowship, the EXIST-Gründerstipendium for the “Lipotools – Lipids in Focus of Pharmacological Drug Development” startup, the Royal Chemical Society Researcher Development Grant, and funding from the Deanship for Research & Innovation, Ministry of Education in Saudi Arabia. His professional experience reflects a strong international footprint, serving as a senior researcher in Berlin since 2017, a visiting scientist at Children’s Cancer Hospital Egypt (57357), and a former CEO of the “Lipotools” startup, alongside progressive academic roles in Suez Canal University. His major scientific interests include drug synthesis and development, small-molecule screening, computer-aided drug design, development of biochemical and enzymatic tools, lipid-based disease research, and drug repurposing to treat human diseases.

Profiles: Scopus | Orcid | Google Scholar

Featured Publications

"Dyslipidemic SPTLC3 Integrates Bile Acid-FXR Signaling with Sphingolipid Remodeling in MASLD", M Visentin, Z Gai, A Kovilakath, F De Luca, G Panteloglou, A Othman, bioRxiv, 2025.

"Editorial on research topic Medicinal Chemistry for Neglected Tropical Diseases Using In-vitro, In-vivo and In Silico Approaches", SN Mali, EM Saied, CBR Dos Santos, J Neves Cruz, Frontiers in Chemistry 13, 2025.

"Integrative Metabolomic, Network Pharmacology, and Experimental Evidence for Lepidium sativum Seed Extract as a Natural Modulator of Pulmonary Fibrosis via the ncNRFR/Let-7d", IM Alanazi, HH Abo Nahas, DI Mohamed, N Hosny, YHA Elewa, Pharmaceuticals 18 (12), 2025.

"Multi-targeted azacoumarin–cyanocinnamate hybrids induce G 2/M arrest and apoptosis via tubulin, and COX-2/VEGFR modulation: insights from in vitro mechanistic basis", MA El-Zend, IM El-Deen, RM Mansour, TA Yousef, AA Alrashidi, RSC Medicinal Chemistry, 2025.

"Exploration of the anticancer efficacy of a novel 1, 3-thiazole analog in an ehrlich ascites carcinoma model: in vivo and in silico insights into hepatorenal protective", M El Behery, DM Abo-Elmatty, M Alsunbul, YIM El-Deen, DI Mohamed, RSC advances 15 (25), 2025.